Scoring hidradenitis suppurativa: How to simplify data collection?

Dear Editor, Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, diagnosed clinically based on the type and location of the lesions, and on the disease course.1 The severity of HS varies greatly between patients and is difficult to quantify. This is strongly influenced by the phenotypical heterogeneity of the disease and implies that a broad range of very different elements must be assessed to encompass the variation adequately. There is no ‘gold standard’ score that would be useful for a universal grading of disease severity, assessing the efficacy of treatments and serving as a basis for management algorithms. More than 30 scores have been developed2 using physicianreported items (elements) like the clinical examination or subjectivebased items like patient reported outcomes (PRO) such as pain. Hitherto, biological biomarkers have not been sufficiently validated. The establishment of HS registries has helped to improve the understanding of the disease. However, an important limitation is the lack of time for the physician to fill the entire registry questionnaire and to calculate the complex and timeconsuming scoring systems. To save time in calculating the scores at the time of data collection, we collect the items needed to calculate certain scores (rather than calculating the score itself) and then calculate the score automatically, for example using Excel formulas. This procedure is used in the European Registry of HS (ERHS) and is one of the major changes between the initial version in 2016 and its update in 2021.3,4 The main advantage of this approach is obviously the time saved by automating the calculations. Moreover, if a new score combining already collected items is developed, it can be calculated retrospectively just by creating the appropriate formula that relates the relevant items. Finally, another advantage is that there is no risk of making a calculation error at the time of consultation, as the calculation is done automatically. It is obviously essential to avoid any error when entering the data as this would be a systematic error. Concerning the ERHS, the formulas used in the spreadsheet (Excel, Microsoft, US) were all done with Received: 29 August 2022 | Accepted: 25 October 2022

[1]  V. del Marmol,et al.  European registry for hidradenitis suppurativa: state of play , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  L. Schmitz,et al.  A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa , 2018, JAMA dermatology.

[3]  G. Jemec,et al.  Hidradenitis Suppurativa: Advances in Diagnosis and Treatment , 2017, JAMA.

[4]  D. Presser,et al.  Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity , 2017, The British journal of dermatology.

[5]  A. Martorell,et al.  Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  V. Piguet,et al.  Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process , 2016, The British journal of dermatology.

[7]  A. Kimball,et al.  HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  A. Kimball,et al.  Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa , 2012, Annals of Internal Medicine.

[9]  E. Prens,et al.  Hurley Staging Refined: A Proposal by the Dutch Hidradenitis Suppurativa Expert Group. , 2017, Acta dermato-venereologica.